Patient info Open main menu

Calamine and Glycerin Cream – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

Medicine status: No longer supplied Details

Medicine strength:
150 mg/gram + 50 mg/gram + 50 mg/gram
Contains active substances:

Summary of Product Characteristics (SmPC) - Calamine and Glycerin cream

1 NAME OF THE MEDICINAL PRODUCT

Calamine and Glycerin Cream

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Ingredients%w/w
Zinc Oxide Ph Eur5
Calamine BP15
Glycerin Ph Eur5

3 PHARMACEUTICAL FORM

Cream

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the relief of sunburn. windburn, rough, dry hands, chapped and tender skin and for the relief of skin irritation.

4.2 Posology and method of administration

For topical application

Adults and Children:

To be applied gently to the affected parts when required.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

For external use only.

Keep all medicines out of the reach of children.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically significant drug interactions known.

May mask x-ray pictures under certain circumstances.

4.6 Fertility, Pregnancy and lactation

The safety of Calamine and Glycerin Cream during pregnancy and lactation has not been established but its use during these periods is not considered to constitute a hazard.

4.7 Effects on ability to drive and use machines

No adverse effects known.

4.8 Undesirable effects

Occasional hypersensitivity reactions.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms of overdosage include anorexia, nausea, vomiting, epigastric discomfort and diarrhoea. Treatment consists of symptomatic measures only.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Calamine has a mild astringent action on the skin. Zinc oxide has mild astringent, soothing and protective qualities.

Glycerol has emollient properties.

5.2 Pharmacokinetic properties

Not available.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Polawax A31

Paraffin light liquid Isopropyl myristate Polysorbate 80 Bentonite

Sodium citrate gran Water purified Liquefied phenol

6.2 Incompatibilities

None known.

6.3 Shelf life

36 months.

6.4 Special precautions for storage

None.

6.5 Nature and contents of container

An internally lacquered collapsible tube with latex welt having a polypropylene or polythene cap, in a cardboard carton.

Pack size: 35 gm.

6.6 Special precautions for disposal

None stated.

7 MARKETING AUTHORISATION HOLDER

Crest Medical Limited

Unit 5 Farrell Industrial Estate

Howley Lane Warrington

WA1 2PB

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 01021/0207

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

Date of First Authorisation: 9 November 1984 Last Renewal: 22 December 1994

10 DATE OF REVISION OF THE TEXT

09/07/2025

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 01021/0207

Last revision stated in the text: 9 July 2025 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Calamine and Glycerin cream

Active substances Calamine, Zinc oxide, Glycerol
Strength 150 mg/gram + 50 mg/gram + 50 mg/gram
Pharmaceutical form Cutaneous cream
How is it taken Cutaneous
Excipients Polawax A31, Paraffin light liquid Isopropyl myristate Polysorbate 80 Bentonite, Sodium citrate gran Water purified Liquefied phenol
Is it available? No, all its packs are listed as discontinued (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 36 months.
Storage None.
Marketing authorisation PL 01021/0207 (first authorised 9 November 1984)
Marketing authorisation holder Crest Medical Limited
Codes BNF 13030000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.